The knowledge of an inverse relationship between plasma high-density lipoprotein cholesterol (HDL-C) concentrations and rates of cardiovascular disease has led to the concept that increasing plasma HDL-C levels would be protective against cardiovascular events. Therapeutic interventions presently available to correct the plasma lipid profile have not been designed to specifically act on HDL, but have modest to moderate effects on plasma HDL-C concentrations. Statins, the first-line lipid-lowering drug therapy in primary and secondary cardiovascular prevention, have quite modest effects on plasma HDL-C concentrations (2–10 %). Fibrates, primarily used to reduce plasma triglyceride levels, also moderately increase HDL-C levels (5–15 %). Niacin is the most potent available drug in increasing HDL-C levels (up to 30 %), but its use is limited by side effects, especially flushing. The present chapter reviews the effects of established hypolipidemic drugs (statins, fibrates, and niacin) on plasma HDL-C levels and HDL subclass distribution, and on HDL functions, including cholesterol efflux capacity, endothelial protection, and antioxidant properties.

Effects of established hypolipidemic drugs on HDL concentration, subclass distribution, and function / M. Gomaraschi, M.P. Adorni, M. Banach, F. Bernini, G. Franceschini, L. Calabresi (HANDBOOK OF EXPERIMENTAL PHARMACOLOGY). - In: High density lipoproteins : from biological understanding to clinical exploitation / [a cura di] A. von Eckardstein, D. Kardassis. - New York : Springer, 2015. - ISBN 9783319096643. - pp. 593-615 [10.1007/978-3-319-09665-0_19]

Effects of established hypolipidemic drugs on HDL concentration, subclass distribution, and function

M. Gomaraschi
Primo
;
G. Franceschini
Penultimo
;
L. Calabresi
2015

Abstract

The knowledge of an inverse relationship between plasma high-density lipoprotein cholesterol (HDL-C) concentrations and rates of cardiovascular disease has led to the concept that increasing plasma HDL-C levels would be protective against cardiovascular events. Therapeutic interventions presently available to correct the plasma lipid profile have not been designed to specifically act on HDL, but have modest to moderate effects on plasma HDL-C concentrations. Statins, the first-line lipid-lowering drug therapy in primary and secondary cardiovascular prevention, have quite modest effects on plasma HDL-C concentrations (2–10 %). Fibrates, primarily used to reduce plasma triglyceride levels, also moderately increase HDL-C levels (5–15 %). Niacin is the most potent available drug in increasing HDL-C levels (up to 30 %), but its use is limited by side effects, especially flushing. The present chapter reviews the effects of established hypolipidemic drugs (statins, fibrates, and niacin) on plasma HDL-C levels and HDL subclass distribution, and on HDL functions, including cholesterol efflux capacity, endothelial protection, and antioxidant properties.
HDL; HDL subclasses; cell cholesterol efflux; endothelial cells; statins; fibrates; niacin
Settore BIO/14 - Farmacologia
2015
Book Part (author)
File in questo prodotto:
File Dimensione Formato  
chp%3A10.1007%2F978-3-319-09665-0_19.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 248.41 kB
Formato Adobe PDF
248.41 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/254522
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 23
  • ???jsp.display-item.citation.isi??? 17
social impact